Nivolumab Survival Benefit Continues in Squamous Cell NSCLCNivolumab Survival Benefit Continues in Squamous Cell NSCLC
Updated results of the CheckMate 017 study show that after 18 months, patients treated with nivolumab continue to have better survival as compared with docetaxel. Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Docetaxel | Hematology | Non-Small Cell Lung Cancer | Squamous Cell Carcinoma | Study | Taxotere